2026 Q2 - tulosraportti
43 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 431 | - | - | ||
| 55 | - | - | ||
| 124 | - | - | ||
| 1 076 | - | - | ||
| 3 220 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·20 t sittenthis is bull for VB10.NEO partner process: https://www.businesswire.com/news/home/20261007586639/en/Tempus-Announces-Multi-Year-Collaboration-with-Moderna-and-Merck?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark
I still think the market is pricing in very little of the potential in Nykode and the position they hold now. The Tempus deal with Moderna/Merck also shows that the infrastructure surrounding individualized cancer vaccines is starting to be built for commercial scale. I also noticed that Nykode is now looking for a Senior CMC Manager / Specialist in Oslo/Lyngby (ref. https://jobs.recruitment.simployer.com/nykode/senior-cmc-manager-specialist-oslo-no-or-lyngby-dk/view-job?q=desc&isFrame=false). It becomes extra interesting when viewed together with the hiring of Jakob Helding Rasmussen as CTO, with heavy CMC and manufacturing experience from, among other things, nearly 12 years at Novo Nordisk. Of course, it does not mean the world on its own, but I think it is an interesting signal that Nykode is building capacity around development and manufacturing while VB10.NEO, NeoSELECT, and the rest of the pipeline mature. If good news comes from the company, we will see completely different share price levels. Hopefully, the management's call options at 7 kr will also gain good value for them eventually.
·1 päivä sitten · MuokattuFirst time posting a positive comment., or bulling as it is often said., here it blows soon🫡
could well be that you are right Donnie, looks like there is support for 3.54 and that could mean that short selling is done, Everyone wants the stock to go upwards even those who try to press the price down to buy cheap.- ·3 päivää sittenInteresting article about what is happening in biotech right now: https://www.finansavisen.no/helse/2026/10/04/8385012/gullrush-i-biotek Nykode is, in my opinion, strategically positioned right in the sweet spot. If you, like me, have great faith in the combination of artificial intelligence and biotech, I think Nykode is the most interesting case on the Oslo Stock Exchange. Part of what I find particularly exciting is the data the company has built up over nearly 20 years. This applies not only to the trials that have succeeded. Also data from experiments that did not yield the desired result can be valuable when teaching models what does not work. All historical data has been preserved, and during the Q&A after the Q2 presentation, Agnete Fredriksen was asked whether new data is fed back into NeoSELECT and used to make the model better over time. The answer was yes. It is precisely this that Finansavisen describes as "lab-in-the-loop": the model suggests, the laboratory tests, the results are fed back, and the next round can be better. This does not mean that AI alone makes Nykode a winner. Clinical results are still what counts. But if Nykode manages to combine 20 years of biological data, NeoSELECT, its own laboratory tests and clinical data in an increasingly better learning loop, then in my opinion it could become a significant competitive advantage. This is a part of the Nykode case that I believe the market is currently paying relatively little attention to. The AI models can eventually be accessed by everyone. 20 years of proprietary biological and clinical data cannot simply be downloaded.
·2.10.It goes without saying that they bought over 500,000 :)
Don't know if I would say it "goes without saying" to put that much into a pennystock. With that said, it is a better one of its kind.- ·2.10. · MuokattuExciting change in the top 50 yesterday, BNP Paribas onto the list with over 1.5 mill shares which means they must have bought at least 50,000 yesterday.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
43 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·20 t sittenthis is bull for VB10.NEO partner process: https://www.businesswire.com/news/home/20261007586639/en/Tempus-Announces-Multi-Year-Collaboration-with-Moderna-and-Merck?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmarkI still think the market is pricing in very little of the potential in Nykode and the position they hold now. The Tempus deal with Moderna/Merck also shows that the infrastructure surrounding individualized cancer vaccines is starting to be built for commercial scale. I also noticed that Nykode is now looking for a Senior CMC Manager / Specialist in Oslo/Lyngby (ref. https://jobs.recruitment.simployer.com/nykode/senior-cmc-manager-specialist-oslo-no-or-lyngby-dk/view-job?q=desc&isFrame=false). It becomes extra interesting when viewed together with the hiring of Jakob Helding Rasmussen as CTO, with heavy CMC and manufacturing experience from, among other things, nearly 12 years at Novo Nordisk. Of course, it does not mean the world on its own, but I think it is an interesting signal that Nykode is building capacity around development and manufacturing while VB10.NEO, NeoSELECT, and the rest of the pipeline mature. If good news comes from the company, we will see completely different share price levels. Hopefully, the management's call options at 7 kr will also gain good value for them eventually.
- ·1 päivä sitten · MuokattuFirst time posting a positive comment., or bulling as it is often said., here it blows soon🫡could well be that you are right Donnie, looks like there is support for 3.54 and that could mean that short selling is done, Everyone wants the stock to go upwards even those who try to press the price down to buy cheap.
- ·3 päivää sittenInteresting article about what is happening in biotech right now: https://www.finansavisen.no/helse/2026/10/04/8385012/gullrush-i-biotek Nykode is, in my opinion, strategically positioned right in the sweet spot. If you, like me, have great faith in the combination of artificial intelligence and biotech, I think Nykode is the most interesting case on the Oslo Stock Exchange. Part of what I find particularly exciting is the data the company has built up over nearly 20 years. This applies not only to the trials that have succeeded. Also data from experiments that did not yield the desired result can be valuable when teaching models what does not work. All historical data has been preserved, and during the Q&A after the Q2 presentation, Agnete Fredriksen was asked whether new data is fed back into NeoSELECT and used to make the model better over time. The answer was yes. It is precisely this that Finansavisen describes as "lab-in-the-loop": the model suggests, the laboratory tests, the results are fed back, and the next round can be better. This does not mean that AI alone makes Nykode a winner. Clinical results are still what counts. But if Nykode manages to combine 20 years of biological data, NeoSELECT, its own laboratory tests and clinical data in an increasingly better learning loop, then in my opinion it could become a significant competitive advantage. This is a part of the Nykode case that I believe the market is currently paying relatively little attention to. The AI models can eventually be accessed by everyone. 20 years of proprietary biological and clinical data cannot simply be downloaded.
- ·2.10.It goes without saying that they bought over 500,000 :)Don't know if I would say it "goes without saying" to put that much into a pennystock. With that said, it is a better one of its kind.
- ·2.10. · MuokattuExciting change in the top 50 yesterday, BNP Paribas onto the list with over 1.5 mill shares which means they must have bought at least 50,000 yesterday.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 431 | - | - | ||
| 55 | - | - | ||
| 124 | - | - | ||
| 1 076 | - | - | ||
| 3 220 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
43 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·20 t sittenthis is bull for VB10.NEO partner process: https://www.businesswire.com/news/home/20261007586639/en/Tempus-Announces-Multi-Year-Collaboration-with-Moderna-and-Merck?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmarkI still think the market is pricing in very little of the potential in Nykode and the position they hold now. The Tempus deal with Moderna/Merck also shows that the infrastructure surrounding individualized cancer vaccines is starting to be built for commercial scale. I also noticed that Nykode is now looking for a Senior CMC Manager / Specialist in Oslo/Lyngby (ref. https://jobs.recruitment.simployer.com/nykode/senior-cmc-manager-specialist-oslo-no-or-lyngby-dk/view-job?q=desc&isFrame=false). It becomes extra interesting when viewed together with the hiring of Jakob Helding Rasmussen as CTO, with heavy CMC and manufacturing experience from, among other things, nearly 12 years at Novo Nordisk. Of course, it does not mean the world on its own, but I think it is an interesting signal that Nykode is building capacity around development and manufacturing while VB10.NEO, NeoSELECT, and the rest of the pipeline mature. If good news comes from the company, we will see completely different share price levels. Hopefully, the management's call options at 7 kr will also gain good value for them eventually.
- ·1 päivä sitten · MuokattuFirst time posting a positive comment., or bulling as it is often said., here it blows soon🫡could well be that you are right Donnie, looks like there is support for 3.54 and that could mean that short selling is done, Everyone wants the stock to go upwards even those who try to press the price down to buy cheap.
- ·3 päivää sittenInteresting article about what is happening in biotech right now: https://www.finansavisen.no/helse/2026/10/04/8385012/gullrush-i-biotek Nykode is, in my opinion, strategically positioned right in the sweet spot. If you, like me, have great faith in the combination of artificial intelligence and biotech, I think Nykode is the most interesting case on the Oslo Stock Exchange. Part of what I find particularly exciting is the data the company has built up over nearly 20 years. This applies not only to the trials that have succeeded. Also data from experiments that did not yield the desired result can be valuable when teaching models what does not work. All historical data has been preserved, and during the Q&A after the Q2 presentation, Agnete Fredriksen was asked whether new data is fed back into NeoSELECT and used to make the model better over time. The answer was yes. It is precisely this that Finansavisen describes as "lab-in-the-loop": the model suggests, the laboratory tests, the results are fed back, and the next round can be better. This does not mean that AI alone makes Nykode a winner. Clinical results are still what counts. But if Nykode manages to combine 20 years of biological data, NeoSELECT, its own laboratory tests and clinical data in an increasingly better learning loop, then in my opinion it could become a significant competitive advantage. This is a part of the Nykode case that I believe the market is currently paying relatively little attention to. The AI models can eventually be accessed by everyone. 20 years of proprietary biological and clinical data cannot simply be downloaded.
- ·2.10.It goes without saying that they bought over 500,000 :)Don't know if I would say it "goes without saying" to put that much into a pennystock. With that said, it is a better one of its kind.
- ·2.10. · MuokattuExciting change in the top 50 yesterday, BNP Paribas onto the list with over 1.5 mill shares which means they must have bought at least 50,000 yesterday.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 431 | - | - | ||
| 55 | - | - | ||
| 124 | - | - | ||
| 1 076 | - | - | ||
| 3 220 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt